Clinical Trial Update: Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 double-blind, randomized, placebo-controlled trial of CC-10004 in moderate-to-severe plaque psoriasis completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• CC-10004

Snippet

Sponsor: Amgen | Conditions: Psoriasis | Phase 2 | Status: COMPLETED